FDA Advisers Recommend Carvykti and Abecma for Earlier Use in Cancer Patients
Washington, D.C. – Amid concerns of early patient deaths, FDA advisors have given their support to Johnson & Johnson and Legend Biotech’s Carvykti, as well as Bristol Myers Squibb’s Abecma for use in earlier stages of treatment. The panel of experts reviewed data for these CAR-T cell therapies which target cancer cells more effectively. Even … Read more